/home/ejo ORIGINAL RESEARCH ARTICLE vanced AMD, it is only responsible for nearly 20% of all cases of legal blindness (2). On the other hand, the neovascular type affects about 10%-15% of individuals, but accounts for approximately 90% of all cases of AMD-induced severe vision loss (1, 3).
Introduction
Age-related macular degeneration (AMD) is the leading cause of visual loss in people over 50 years of age in developed countries and causes visual loss in nearly 10% of those >65 years of age and in >25% of those >75 years of age (1) . Age-related macular degeneration has been clinically classified into 3 groups: early, intermediate, and advanced AMD. Advanced AMD consists of atrophic and neovascular forms. Though atrophic type accounts for 85%-90% of cases of ad-properties) were found to be impaired in the patients with severe neovascular AMD (bilateral or larger CNV) (15) . So it is not clear that the role of stem cells in the CNV process is beneficial or detrimental due to impaired functional properties despite increased levels.
Optical coherence tomography (OCT) allows in vivo crosssectional visualization of pathologic changes in the clinical course of AMD. Hence, evaluating the stem cell levels with clinical and OCT findings of the patients with neovascular type AMD might enlighten the role of stem cells in the CNV process in AMD.
Therefore, the main purposes of this study are to evaluate whether there is any relationship between clinical and OCT findings and stem cell levels and, as a secondary purpose, to confirm previous studies reporting increased stem cell levels in neovascular type AMD by comparing the stem cell levels in the patients with neovascular type AMD with healthy subjects.
Methods
This study was conducted in the Ulucanlar Eye Training and Research Hospital according to the Declaration of Helsinki and approved by the Ankara University Non-interventional Clinical Researches Ethics Committee.
The study was conducted by counting CD34(+) stem cells in blood materials obtained in routine preoperative analysis of 2 patient groups: 1) patients diagnosed with neovascular type AMD both clinically and angiographically and in whom intravitreal ranibizumab injection is planned (first dose or repeated dose); and 2) patients planned to have cataract surgery and in whom there is no history and/or clinical findings of any type of AMD.
Patients were informed about the study and a consent form was obtained from each one. They were informed that part of their blood sample obtained for routine preoperative analysis would be used for this purpose.
Demographic data, best-corrected visual acuity levels, and the findings of the anterior segment and fundus examinations were recorded. Dilated fundus examination was performed by using a 90-diopter lens. Color fundus pictures, fluorescein angiography (FA), and OCT images of the patients with neovascular type AMD were also recorded and evaluated. Visual acuity levels obtained via Snellen chart were converted to logarithm of minimum angle of resolution (log-MAR) for statistical analysis. Smoking status was defined according to current and former smoking.
A total of 55 patients were enrolled in the study. Of these, 28 were in the study group and 27 in the control group. Patients with CNV related to other etiologies, patients with ocular neovascularization other than CNV (cornea, iris, or angle), and patients with low vision that could not be explained by the cataract level were excluded. Patients treated with any therapy that may result in bone marrow suppression or treated with radiation due to any reason during the last year; patients with cerebrovascular attack history, proliferative diabetic retinopathy, or hypertensive retinopathy; patients with history of any major surgery or myocardial infarction within the last 6 months; patients using medications like anticoagulants or statins that can affect stem cell levels; and patients with any acute disease at the time of blood sample collections were also excluded.
Flow cytometry analysis was performed 6-8 hours later. After collection, blood samples for each donor sample were transported to the laboratory. Analysis of blood samples was Figure 1 .
During data analysis, most debris, platelets, and unlysed erythrocytes (i.e., CD45neg) are excluded (R1 in Fig. 1 ). The CD45 dim border of the CD45 window (R1) is verified on and macular hypopigmentation (areas of focal atrophy of the RPE on biomicroscopic examination and window defects corresponding to hypopigmentation areas on FA), geographic atrophy (loss of RPE in sharply delineated area with the visible choroidal vessels on biomicroscopic examination and sharply delineated hyperfluorescence due to window defect on FA), lipid exudation (accumulation of lipid in or under the retina within macula without other retinal vascular disease, causing yellow spots on biomicroscopic examination and dark areas on FA), subretinal hemorrhage (blood located between the RPE and the neurosensory retina, causing retinal elevation detectable on biomicroscopic examination and blockage of the fluorescence caused by the hemorrhage on FA), and subretinal fibrosis (defined as a well-defined white or yellow solid fibrous tissue on biomicroscopic examination and as hyperfluorescent appearance of fibrous tissue and loss of choroidal fluorescence due to blockage on FA). Representative fundus and FA images for the clinical findings are presented in Figure 2 .
OCT findings were defined as drusen (undulations and elevations in the hyperreflective band of the RPE with hyperreflectivity and some areas of hyporeflectivity within the lesion) and pigment epithelial detachment (PED) (separation of the hyperreflective band of the RPE from Bruch membrane) including drusenoid (areas of RPE elevation, typically smooth in contour and with medium to high, but homogenous, internal reflectivity), fibrovascular (smooth or irregular elevations of the RPE with heterogeneous internal reflectivity, featuring areas of hyperreflectivity as well as pockets of hyporeflectivity), and hemorrhagic PED (a dome-shaped RPE detachment with optical shadowing of choroidal layers), intraretinal fluid (diffuse accumulation causing increased retinal thickness and reduced retinal reflectivity or localized accumulation causing cysts with low reflectivity), and scarring (areas of nodular hyperreflectivity with deformation or irregularity of adjacent retina and RPE). Representative images for OCT findings are presented in Figure 3 .
Statistical analysis was performed using SPSS v.21.0 for Windows (IBM Corp.). Continuous variables are presented as mean ± SD; categorical variables are defined as number and percentage. Chi-square test and Fisher's exact test were used for categorical variables. After evaluation of normal distribution performed by using Kolmogorov-Smirnov and ShapiroWilk test, the differences between the means were carried out by using the t-test for normally distributed data and using the Mann-Whitney U test for data that did not conform to the normal distribution.
Additionally, binary logistic regression analysis with enter method was performed for adjusting potential confounding effect of age and sex on the stem cell levels. In the analysis, age, sex, and stem cell levels were used as independent variables and group was used as dependent variable. p Values <0.05 were considered to be significant.
Results
A total of 55 patients, 30 male (54.5%) and 25 female (45.5%), between 54 and 83 years of age (mean 69.9 ± 6.7 years) were enrolled. There was no significant difference between groups in terms of age and sex; however, visual acuity was significantly better in the control vs the AMD group (p<0.01, t-test). Groups a CD45 vs CD34 plot of ungated data in order to prevent exclusion of any CD34(+) events at this stage. The selected leucocytes (R1) are then displayed in a CD34 vs SSC dot plot (R2 in Fig. 1 ). The CD34(+) events are selected (R2) and displayed on a CD45 vs SSC dot plot (R3 in Fig. 1 ). The cluster of SSClow, CD45dim events is selected and displayed on FSC vs SSC dot plot (R4 in Fig. 1 ). The true CD34(+) count thus has to fulfil the criteria of R1, R2, R3, and R4 and is expressed as a fraction of leucocytes.
For the local dual-platform assays, the absolute CD34(+) cell numbers were calculated by multiplying the flow cytometrically obtained percent CD34(+) cells by the white blood cell count from ABX Micros ES 60 hematology analyzer (Horiba ABX SAS).
Clinical findings were defined as soft drusen (large and cluster of yellow deposits under the retina on fundus image and hyperfluorescent lesions with a poorly defined contour on FA), pigment anomaly including macular hyperpigmentation (areas of hypertrophy of the retinal pigment epithelium [RPE] on biomicroscopic examination and blocked fluorescence corresponding to hyperpigmentation areas on FA) were compared for the association of systemic diseases and smoking status and smoking rate was significantly higher in the AMD group (66.7%) compared to the control group (37%) (p = 0.02, chi-square test). Age, sex, visual acuity levels, and baseline clinical characteristics (systemic diseases and status of smoking) of the groups are shown in Table I .
The mean CD34(+) stem cell level in the AMD group was 1.5 ± 0.9 cells/µL; in the control group, it was 0.5 ± 0.3 cells/µL. The mean percentage of circulating CD34(+) stem cells in the AMD group was 0.02 ± 0.01 (% of CD45); in the control group, 0.01 ± 0.01 (% of CD45). Stem cell levels and percentages in the peripheral blood were significantly higher in the AMD group (p<0.001, Mann-Whitney U test) (Tab. II). Even after adjusting for age and sex, there was still a significant difference between groups (Tab. III).
Circulating CD34(+) stem cell percentage and levels were analyzed for association with ocular findings in the AMD group and no significant difference was observed in these parameters. 
Discussion
Neovascularization occurs in many postnatal physiologic and pathologic processes. In the early 1990s, this process was thought to occur only via angiogenesis. However, this opinion has changed after the study by Asahara et al (17) , showing that cells expressing CD34 obtained from mouse peripheral blood sample could differentiate to endothelium cells in vitro.
Subsequent studies showed that the vasculogenesis continues also in the postnatal period. In 1999, Asahara et al (12) realized a labeled stem cell transplantation in a mice model and showed that these stem cells were involved in both physiologic processes, such as ovulation and wound healing, and in pathologic processes, such as tumor growth, myocardial ischemia, and corneal neovascularization. Given that CD34(+) cells have a contribution in the basic pathologic processes of neovascularization, one may suggest that it plays a role in CNV and related complications.
In an immunohistochemical study by Espinosa-Heidmann et al (14) , experimentally developed CNV in mice transplanted with labeled stem cells was evaluated. They observed that 17% of the cell population in the lesion side consisted of labeled stem cells. In a similar study conducted by Sengupta et al (18) , experimentally formed CNV was investigated in mice transplanted with labeled stem cells by using both confocal microscopy and immunohistochemistry. The authors found that 50% of the vascular structure in lesion was derived from transplanted stem cells. In a study conducted by the same group in 2005, when adhesion molecules such as SDF-1 and CD144 playing a role in stem cells' migration toward target tissues were inhibited, experimentally formed CNVs were found to be significantly smaller than in the control group (19) .
After all these experimental studies, Yodoi et al (15) evaluated stem cell levels and functions in patients with AMD with CNV and found that CD34(+) levels were significantly higher compared to the healthy control group. Furthermore, CD34(+) stem cell functions were found to be significantly impaired in the severe AMD group (bilateral or larger CNV). When the relationship between stem cell and CNV is evaluated from another aspect, it is intriguing that VEGF, which is a major target for the treatment of AMD, is also a basic regulator in vasculogenesis. Following VEGF secreting myoblast implantation, Springer and coworkers (20) observed vasculogenesis in mouse leg with nonischemic structure. Similarly, Asahara et al (21) observed that VEGF increased mobilization of stem cells from bone marrow and exacerbated the neovascularization by accelerating the differentiation of these stem cells. In another study, a correlation was found between plasma VEGF levels and CD34(+) stem cell count in circulation (22) . Also, not only ischemia-induced endogenous hematopoietic and angiogenic factors but also statin group drugs, which have endothelium activation and angiogenesis induction roles, have been found to play a role in increasing mobilization of stem cells from bone marrow (23) .
Following the discovery of this relationship between stem cells and neovascularization, changes of stem cells in vascular pathologies were discussed in many studies. In one of the most prominent studies, a decrease in endothelial progenitor cells count and failure in cell migration have been shown in patients with coronary artery diseases (24) . Experimentally developed hindlimb ischemia in mice and myocardial ischemia in rats showed an increase in neovascularization in ischemic areas after transplantation of progenitor cells. Similar improvement in neovascularization also provided in rats with cerebrovascular disease following transplantation of progenitor cells and stem cells. Hence, "therapeutic angiogenesis" has been suggested as a new nomenclature (25, 26) .
Although our result of higher stem cell count in patients with neovascular type AMD conforms with those of the previous studies, its role in this process is still unclear. Therefore, it is important to evaluate the functional capacities of these stem cells. Experimental studies in rats showed that stem cells in younger ones formed healthier corneal vascularization than in older ones (27) . Another study showed stem cell migration capacity was higher in younger individuals compared to older individuals, and also was significantly lower in patients with bilateral and wide CNV (15) . Another remarkable finding regarding stem cell functions is the decreased stem cell functions in healthy smokers (28) .
In light of these data, it is not known at the moment if stem cells have a worsening or a protector effect on the CNV process. Especially during the leakage of newly formed vessels within the process, these cells may have a role in enabling vessel maturation. In factors such as aging and smoking that have a contribution to AMD pathogenesis, functional capacities of stem cells are decreased. On the other hand, decreased functional capacities of the stem cells are also seen in patients with wide lesion and bilateral involvement. Hence it can be claimed that functional capacities of the stem cells could have a protector effect on the development of AMD.
In this respect, evaluation of stem cell levels with clinical findings may be important for the assessment of their roles in CNV in AMD. In our study, we did not find any relationship with the clinical findings. However, larger studies may contribute to clarify this issue.
In conclusion, investigation of functional properties of the stem cells like migration, proliferation, and differentiation and evaluation with clinical findings would be useful in terms of revealing their exact roles in the CNV process. Therefore, therapeutic angiogenesis process occurring in healthy and young functional cells might be helpful in the prevention of complications by enabling maturation of newly formed vessels and removing the ischemic factors that worsen the process.
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